Reply to Commentary by Cummings (2022): Surrogate endpoints extend beyond biomarkers

被引：1
|
作者：
Manyara, Anthony Muchai [1 ]
Ciani, Oriana [2 ]
Taylor, Rod S. [1 ,3 ]
机构：
[1] Univ Glasgow, MRC CSO Social & Publ Hlth Sci Unit, Berkeley Sq,99 Berkeley St, Glasgow G3 7HR, Lanark, Scotland
[2] SDA Bocconi Sch Management, Milan, Italy
[3] Univ Glasgow, Roberston Ctr Biostat, Inst Hlth & Wellbeing, Glasgow, Lanark, Scotland
来源：
ALZHEIMERS & DEMENTIA-TRANSLATIONAL RESEARCH & CLINICAL INTERVENTIONS | 2022年 / 8卷 / 01期
基金：
英国医学研究理事会;
关键词：
D O I：
10.1002/trc2.12344
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Biomarkers for early detection and as surrogate endpoints in cancer prevention trials: issues and opportunities
    Dunn, B.
    EJC SUPPLEMENTS, 2010, 8 (02): : 2 - 2
  • [42] Benefits of Preparticipation Evaluation Extend Beyond Cardiac Screening Reply
    Schefft, Matt
    Schroeder, Alan R.
    Quinonez, Ricardo
    AMERICAN FAMILY PHYSICIAN, 2019, 100 (09) : 521 - 521
  • [43] Biomarkers and surrogate endpoints in renal transplantation:: Present status and considerations for clinical trial design
    Lachenbruch, PA
    Rosenberg, AS
    Bonvini, E
    Cavaillé-Coll, MW
    Colvin, RB
    AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 (04) : 451 - 457
  • [44] Clinical Trials of Cannabidiol for Substance Use Disorders: Outcome Measures, Surrogate Endpoints, and Biomarkers
    Morel, Alix
    Lebard, Pierre
    Dereux, Alexandra
    Azuar, Julien
    Questel, Frank
    Bellivier, Frank
    Marie-Claire, Cynthia
    Fatseas, Melina
    Vorspan, Florence
    Bloch, Vanessa
    FRONTIERS IN PSYCHIATRY, 2021, 12
  • [45] Utility and costs of surrogate endpoints (SEs) and biomarkers in phase I oncology trials.
    Goulart, BHL
    Roberts, TG
    Clark, JW
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 522S - 522S
  • [46] BIOMARKERS, INTERMEDIATE OUTCOMES, AND SURROGATE ENDPOINTS: USES AND MISUSES IN CARDIOVASCULAR BEHAVIORAL MEDICINE RESEARCH
    Salmoirago-Blotcher, Elena
    ANNALS OF BEHAVIORAL MEDICINE, 2019, 53 : S198 - S198
  • [47] The validity of biomarkers as surrogate endpoints in Alzheimer’s disease by means of the Quantitative Surrogate Validation Level of Evidence Scheme (QSVLES)
    C. C. Gispen-De Wied
    M. Kritsidima
    A. J. A. Elferink
    JNHA - The Journal of Nutrition, Health and Aging, 2009, 13 : 376 - 387
  • [48] The validity of biomarkers as surrogate endpoints in Alzheimer's disease by means of the Quantitative Surrogate Validation Level of Evidence Scheme (QSVLES)
    Gispen-De Wied, C. C.
    Kritsidima, M.
    Elferink, A. J. A.
    JOURNAL OF NUTRITION HEALTH & AGING, 2009, 13 (04): : 376 - 387
  • [49] Beyond the Paleolithic prescription: Authors' reply to Commentary
    Turner, Bethany L.
    Thompson, Amanda L.
    NUTRITION REVIEWS, 2014, 72 (04) : 287 - 288
  • [50] Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: Criteria, validation, strategies
    Lesko, LJ
    Atkinson, AJ
    ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2001, 41 : 347 - 366
12345